Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension

dc.contributor.authorBianchi, G.en_US
dc.contributor.authorCzerwinski, E.en_US
dc.contributor.authorKenwright, A.en_US
dc.contributor.authorBurdeska, A.en_US
dc.contributor.authorRecker, R. R.en_US
dc.contributor.authorFelsenberg, D.en_US
dc.contributor.cuauthorRecker, Robert R.en_US
dc.date.accessioned2014-06-27T13:48:44Z
dc.date.available2014-06-27T13:48:44Z
dc.date.issued2012en_US
dc.date.year2012en_US
dc.description.issue6en_US
dc.description.pages1769-1778en_US
dc.description.volume23en_US
dc.identifier.citationBianchi, G.; Czerwinski, E.; Kenwright, A.; Burdeska, A.; Recker, R. R.; Felsenberg, D. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International. 2012, 23(6):1769-1778.en_US
dc.identifier.issn1433-2965en_US
dc.identifier.issn0937-941Xen_US
dc.identifier.pmid21975558en_US
dc.identifier.urihttp://hdl.handle.net/10504/61053
dc.program.unitSchool of Medicineen_US
dc.program.unitDepartment of Medicineen_US
dc.program.unitGeneral Internal Medicineen_US
dc.program.unitEndocrinologyen_US
dc.program.unitOsteoporosisen_US
dc.titleLong-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extensionen_US
dc.title.workOsteoporosis Internationalen_US
dc.typeJournal Articleen_US
dc.url.link1http://dx.doi.org/10.1007/s00198-011-1793-9en_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: